David Cella

Active 1986–2025

524
Papers
132,451
Citations
185
h-index
501
i10-index

Citations

Citations per year for David Cella1956: 2 citations1961: 2 citations1971: 1 citations1982: 1 citations1985: 1 citations1986: 1 citations1987: 2 citations1988: 1 citations1989: 5 citations1990: 6 citations1991: 6 citations1992: 15 citations1993: 22 citations1994: 35 citations1995: 44 citations1996: 72 citations1997: 98 citations1998: 95 citations1999: 149 citations2000: 209 citations2001: 256 citations2002: 384 citations2003: 468 citations2004: 498 citations2005: 648 citations2006: 588 citations2007: 772 citations2008: 784 citations2009: 826 citations2010: 964 citations2011: 984 citations2012: 866 citations2013: 1,019 citations2014: 948 citations2015: 1,043 citations2016: 1,026 citations2017: 1,049 citations2018: 1,031 citations2019: 3,952 citations2020: 4,028 citations2021: 3,705 citations2022: 2,771 citations2023: 1,878 citations2024: 3,489 citations2025: 1,151 citations2026: 35 citations1957–1960: no citations, so these years are not shown1962–1970: no citations, so these years are not shown1972–1981: no citations, so these years are not shown1983–1984: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 13,176 citing papers, 31.6% of this breakdownUnited Kingdom: 3,392 citing papers, 8.1% of this breakdownCanada: 2,470 citing papers, 5.9% of this breakdownGermany: 1,897 citing papers, 4.5% of this breakdownAustralia: 1,807 citing papers, 4.3% of this breakdownItaly: 1,702 citing papers, 4.1% of this breakdownNetherlands: 1,633 citing papers, 3.9% of this breakdownChina: 1,626 citing papers, 3.9% of this breakdownFrance: 1,377 citing papers, 3.3% of this breakdownSpain: 1,120 citing papers, 2.7% of this breakdownJapan: 1,008 citing papers, 2.4% of this breakdownSwitzerland: 783 citing papers, 1.9% of this breakdown
0%31.6%Other 23.4%

Fields

  • Medicine73.8%
  • Biochemistry, Genetics and Molecular Biology5.6%
  • Psychology4.6%
  • Health Professions3.6%
  • Economics, Econometrics and Finance2.9%
  • Neuroscience2.7%
  • Other6.8%

Topics

  • Cancer survivorship and care7.4%
  • Childhood Cancer Survivors' Quality of Life2.1%
  • Cancer-related cognitive impairment studies2.1%
  • Health Systems, Economic Evaluations, Quality of Life1.4%
  • Palliative Care and End-of-Life Issues1.3%
  • Cancer Treatment and Pharmacology1.3%
  • Other84.4%

Coauthors

All papers

Open in search
  1. The Patient-Reported Outcomes Measurement Information System (PROMIS) developed and tested its first wave of adult self-reported health outcome item banks: 2005–2008

    Authors: , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Epidemiology 2010 cited by 5,105

  2. Interpreting the Clinical Importance of Treatment Outcomes in Chronic Pain Clinical Trials: IMMPACT Recommendations

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Christine Rauschkolb, Dennis A. Revicki, Margaret Rothman, Kenneth E. Schmader, Brett R. Stacey, Joseph Stauffer, Thorsten von Stein, Richard E. White, James Witter, Stojan Zavisic - Journal of Pain 2007 cited by 3,405

  3. The Functional Assessment of Cancer Therapy scale: development and validation of the general measure.

    Authors: , , , , , , , , , - Journal of Clinical Oncology 1993 cited by 6,031

  4. Development of physical and mental health summary scores from the patient-reported outcomes measurement information system (PROMIS) global items

    Authors: , , , , - Quality of Life Research 2009 cited by 2,001

  5. Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes

    Authors: , , , - Journal of Clinical Epidemiology 2007 cited by 2,384

  6. The Patient-Reported Outcomes Measurement Information System (PROMIS)

    Authors: , , , , , , , , , - Medical Care 2007 cited by 3,136

  7. Item Banks for Measuring Emotional Distress From the Patient-Reported Outcomes Measurement Information System (PROMIS®): Depression, Anxiety, and Anger

    Authors: , , , , , , - Assessment 2011 cited by 2,157

  8. Veliparib with First-Line Chemotherapy and as Maintenance Therapy in Ovarian Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Carol Aghajanian, Michael A. Bookman - New England Journal of Medicine 2019 cited by 929

  9. Minimal important change (MIC): a conceptual clarification and systematic review of MIC estimates of PROMIS measures

    Authors: , , , , , , , - Quality of Life Research 2021 cited by 539

  10. Development of a PROMIS item bank to measure pain interference

    Authors: , , , , , , , , , , - Pain 2010 cited by 1,189

  11. Effect of Electronic Symptom Monitoring on Patient-Reported Outcomes Among Patients With Metastatic Cancer

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , - JAMA 2022 cited by 383

  12. Measuring financial toxicity as a clinically relevant patient‐reported outcome: The validation of the COmprehensive Score for financial Toxicity (COST)

    Authors: , , , , , , , , , , , - Cancer 2016 cited by 882

  13. Measuring fatigue and other anemia-related symptoms with the Functional Assessment of Cancer Therapy (FACT) measurement system

    Authors: , , , , - Journal of Pain and Symptom Management 1997 cited by 1,967

  14. PROMIS® Adult Health Profiles: Efficient Short-Form Measures of Seven Health Domains

    Authors: , , , , , , , , , , , , , , - Value in Health 2019 cited by 676

  15. PROMIS®-29 v2.0 profile physical and mental health summary scores

    Authors: , , , - Quality of Life Research 2018 cited by 682

  16. The Functional Assessment of Chronic Illness Therapy (FACIT) Measurement System: properties, applications, and interpretation.

    Authors: , , - Health and Quality of Life Outcomes 2003 cited by 1,509

  17. Cancer-Related Fatigue, Version 2.2015

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of the National Comprehensive Cancer Network 2015 cited by 937

  18. The development of a financial toxicity patient‐reported outcome in cancer: The COST measure

    Authors: , , , , , , - Cancer 2014 cited by 649

  19. Neuro-QOL

    Authors: , , , , , , , , , , , , , , , , , , , , , , , - Neurology 2012 cited by 780

  20. Pazopanib versus Sunitinib in Metastatic Renal-Cell Carcinoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2013 cited by 1,918

  21. Effects of Testosterone Treatment in Older Men

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Bret Zeldow, J. Richard Landis, Susan S. Ellenberg - New England Journal of Medicine 2016 cited by 864

  22. Carboplatin and Paclitaxel for Advanced Endometrial Cancer: Final Overall Survival and Adverse Event Analysis of a Phase III Trial (NRG Oncology/GOG0209)

    Authors: , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2020 cited by 340

  23. Nivolumab versus everolimus in patients with advanced renal cell carcinoma: Updated results with long‐term follow‐up of the randomized, open‐label, phase 3 CheckMate 025 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Nizar M. Tannir - Cancer 2020 cited by 337

  24. Reliability and validity of the Functional Assessment of Cancer Therapy-Breast quality-of-life instrument.

    Authors: , , , , , , , , - Journal of Clinical Oncology 1997 cited by 1,759